Inspire Investing LLC Increases Stock Holdings in Codexis, Inc. $CDXS

Inspire Investing LLC increased its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 29.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 162,912 shares of the biotechnology company’s stock after buying an additional 36,809 shares during the period. Inspire Investing LLC owned about 0.20% of Codexis worth $398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Integrity Alliance LLC. purchased a new position in shares of Codexis during the 1st quarter valued at approximately $30,000. US Bancorp DE lifted its position in shares of Codexis by 11,125.0% during the 1st quarter. US Bancorp DE now owns 17,960 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 17,800 shares in the last quarter. Invesco Ltd. lifted its position in shares of Codexis by 100.0% during the 1st quarter. Invesco Ltd. now owns 67,447 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 33,716 shares in the last quarter. Clough Capital Partners L P lifted its position in shares of Codexis by 93.8% during the 1st quarter. Clough Capital Partners L P now owns 69,000 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 33,400 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of Codexis during the 1st quarter valued at approximately $288,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Trading Down 3.5%

Shares of CDXS opened at $2.50 on Tuesday. Codexis, Inc. has a 52-week low of $1.90 and a 52-week high of $6.08. The company has a quick ratio of 5.70, a current ratio of 5.82 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average is $2.63 and its two-hundred day moving average is $2.53. The stock has a market cap of $225.68 million, a PE ratio of -3.01 and a beta of 2.50.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. The firm had revenue of $15.33 million during the quarter, compared to analyst estimates of $14.18 million. Research analysts forecast that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on CDXS. Weiss Ratings restated a “sell (e+)” rating on shares of Codexis in a report on Wednesday, October 8th. Wall Street Zen raised shares of Codexis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.